ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-11D8011
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global 13 Valent Pneumococcal Polysaccharide Conjugate Vaccine PCV13 Market Insights and Forecast to 2028
BUY CHAPTERS

Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Research Report 2025

Code: QYRE-Auto-11D8011
Report
July 2025
Pages:72
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Minhai Bio
Kexing Bio
Cansino Bio
Lanzhou Biological Preparations Institute

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market

The global market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13).
The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Report

Report Metric Details
Report Name 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market
CAGR 5%
Segment by Type
  • Serotype 6B
  • 7F Serotype
  • Serotype 9V
  • 14 Serotype
  • Serotype 18C
  • Serotype 19A
  • 19F Serotype
  • 23F Serotype
  • 24F Serotype
  • Other
Segment by Application
  • Infants from 6 Weeks to 15 Months Old
  • Children Aged 15 Months to 5 Years
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Minhai Bio, Kexing Bio, Cansino Bio, Lanzhou Biological Preparations Institute
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market report?

Ans: The main players in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market are Pfizer, Minhai Bio, Kexing Bio, Cansino Bio, Lanzhou Biological Preparations Institute

What are the Application segmentation covered in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market report?

Ans: The Applications covered in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market report are Infants from 6 Weeks to 15 Months Old, Children Aged 15 Months to 5 Years

What are the Type segmentation covered in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market report?

Ans: The Types covered in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market report are Serotype 6B, 7F Serotype, Serotype 9V, 14 Serotype, Serotype 18C, Serotype 19A, 19F Serotype, 23F Serotype, 24F Serotype, Other

Recommended Reports

Pneumococcal and Meningitis Vaccines

Flu & Viral Vaccines

Broader Vaccine Industry

1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Overview
1.1 Product Definition
1.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Type
1.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value Comparison by Type (2024 VS 2031)
1.2.2 Serotype 6B
1.2.3 7F Serotype
1.2.4 Serotype 9V
1.2.5 14 Serotype
1.2.6 Serotype 18C
1.2.7 Serotype 19A
1.2.8 19F Serotype
1.2.9 23F Serotype
1.2.10 24F Serotype
1.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application
1.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value by Application (2024 VS 2031)
1.3.2 Infants from 6 Weeks to 15 Months Old
1.3.3 Children Aged 15 Months to 5 Years
1.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Estimates and Forecasts
1.4.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2020-2031
1.4.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2020-2031
1.4.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Competition by Manufacturers
2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Manufacturers (2020-2025)
2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Manufacturers (2020-2025)
2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Product Type & Application
2.7 Global Key Manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Date of Enter into This Industry
2.8 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Competitive Situation and Trends
2.8.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Players Market Share by Revenue
2.8.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Scenario by Region
3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region: 2020-2031
3.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region: 2020-2025
3.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region: 2026-2031
3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region: 2020-2031
3.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region: 2020-2025
3.3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region: 2026-2031
3.4 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Country
3.4.1 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2020-2031)
3.4.3 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Country
3.5.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2020-2031)
3.5.3 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Region
3.6.1 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2020-2031)
3.6.3 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Country
3.7.1 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2020-2031)
3.7.3 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Country
3.8.1 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2020-2031)
3.8.3 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2020-2031)
4.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2020-2025)
4.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2026-2031)
4.1.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2020-2031)
4.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2020-2031)
4.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2020-2025)
4.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2026-2031)
4.2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2020-2031)
4.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2020-2031)
5 Segment by Application
5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2020-2031)
5.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2020-2025)
5.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2026-2031)
5.1.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2020-2031)
5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2020-2031)
5.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2020-2025)
5.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2026-2031)
5.2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2020-2031)
5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Minhai Bio
6.2.1 Minhai Bio Company Information
6.2.2 Minhai Bio Description and Business Overview
6.2.3 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.2.5 Minhai Bio Recent Developments/Updates
6.3 Kexing Bio
6.3.1 Kexing Bio Company Information
6.3.2 Kexing Bio Description and Business Overview
6.3.3 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.3.5 Kexing Bio Recent Developments/Updates
6.4 Cansino Bio
6.4.1 Cansino Bio Company Information
6.4.2 Cansino Bio Description and Business Overview
6.4.3 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.4.5 Cansino Bio Recent Developments/Updates
6.5 Lanzhou Biological Preparations Institute
6.5.1 Lanzhou Biological Preparations Institute Company Information
6.5.2 Lanzhou Biological Preparations Institute Description and Business Overview
6.5.3 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.5.5 Lanzhou Biological Preparations Institute Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industry Chain Analysis
7.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Mode & Process Analysis
7.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales and Marketing
7.4.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Channels
7.4.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors
7.5 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customer Analysis
8 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Dynamics
8.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industry Trends
8.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Drivers
8.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Challenges
8.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Minhai Bio
Kexing Bio
Cansino Bio
Lanzhou Biological Preparations Institute
List of Tables
 Table 1. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Competitive Situation by Manufacturers in 2024
 Table 4. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Product Type & Application
 Table 12. Global Key Manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2020-2025) & (K Units)
 Table 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2020-2025)
 Table 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2026-2031) & (K Units)
 Table 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2026-2031)
 Table 21. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2020-2025)
 Table 23. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2026-2031)
 Table 25. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2020-2025) & (K Units)
 Table 27. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2026-2031) & (K Units)
 Table 28. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2020-2025) & (K Units)
 Table 32. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2026-2031) & (K Units)
 Table 33. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) by Type (2020-2025)
 Table 51. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) by Type (2026-2031)
 Table 52. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2020-2025)
 Table 53. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2026-2031)
 Table 54. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2020-2025)
 Table 57. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2026-2031)
 Table 58. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (US$/Unit) by Type (2020-2025)
 Table 59. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (US$/Unit) by Type (2026-2031)
 Table 60. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) by Application (2020-2025)
 Table 61. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) by Application (2026-2031)
 Table 62. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2020-2025)
 Table 63. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2026-2031)
 Table 64. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2020-2025)
 Table 67. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2026-2031)
 Table 68. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (US$/Unit) by Application (2020-2025)
 Table 69. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (US$/Unit) by Application (2026-2031)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Minhai Bio Company Information
 Table 76. Minhai Bio Description and Business Overview
 Table 77. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
 Table 79. Minhai Bio Recent Developments/Updates
 Table 80. Kexing Bio Company Information
 Table 81. Kexing Bio Description and Business Overview
 Table 82. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
 Table 84. Kexing Bio Recent Developments/Updates
 Table 85. Cansino Bio Company Information
 Table 86. Cansino Bio Description and Business Overview
 Table 87. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
 Table 89. Cansino Bio Recent Developments/Updates
 Table 90. Lanzhou Biological Preparations Institute Company Information
 Table 91. Lanzhou Biological Preparations Institute Description and Business Overview
 Table 92. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
 Table 94. Lanzhou Biological Preparations Institute Recent Developments/Updates
 Table 95. Key Raw Materials Lists
 Table 96. Raw Materials Key Suppliers Lists
 Table 97. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors List
 Table 98. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customers List
 Table 99. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Trends
 Table 100. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Drivers
 Table 101. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Challenges
 Table 102. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources
 Table 106. Authors List of This Report


List of Figures
 Figure 1. Product Picture of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
 Figure 2. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Type: 2024 & 2031
 Figure 4. Serotype 6B Product Picture
 Figure 5. 7F Serotype Product Picture
 Figure 6. Serotype 9V Product Picture
 Figure 7. 14 Serotype Product Picture
 Figure 8. Serotype 18C Product Picture
 Figure 9. Serotype 19A Product Picture
 Figure 10. 19F Serotype Product Picture
 Figure 11. 23F Serotype Product Picture
 Figure 12. 24F Serotype Product Picture
 Figure 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value by Application (2020-2031) & (US$ Million)
 Figure 14. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Application: 2024 & 2031
 Figure 15. Infants from 6 Weeks to 15 Months Old
 Figure 16. Children Aged 15 Months to 5 Years
 Figure 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size (2020-2031) & (US$ Million)
 Figure 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (2020-2031) & (K Units)
 Figure 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price (US$/Unit) & (2020-2031)
 Figure 21. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Report Years Considered
 Figure 22. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Manufacturers in 2024
 Figure 23. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Manufacturers in 2024
 Figure 24. Global 5 and 10 Largest 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Players: Market Share by Revenue in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in 2024
 Figure 25. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 27. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2020-2031)
 Figure 28. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2020-2031)
 Figure 29. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Canada 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2020-2031)
 Figure 32. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2020-2031)
 Figure 33. Germany 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. France 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. U.K. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Italy 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Russia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2020-2031)
 Figure 39. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2020-2031)
 Figure 40. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Australia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. China Taiwan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Indonesia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Thailand 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Malaysia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2020-2031)
 Figure 50. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. UAE 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Type (2020-2031)
 Figure 60. Global Revenue Market Share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Type (2020-2031)
 Figure 61. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (US$/Unit) by Type (2020-2031)
 Figure 62. Global Sales Market Share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application (2020-2031)
 Figure 63. Global Revenue Market Share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application (2020-2031)
 Figure 64. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (US$/Unit) by Application (2020-2031)
 Figure 65. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Pneumococcal Conjugate Vaccine PCV Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global 13 Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Research Report 2024
23 valent Pneumococcal Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global 13 Valent Pneumococcal Conjugate Vaccine Market Research Report 2024
Global Streptococcus Pneumoniae Polysaccharide Vaccine Market Research Report 2025
Streptococcus Pneumoniae Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GP Vaccination Market Research Report 2025
Global IPV Vaccine Market Research Report 2025
Preventable Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccine Ampoules Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Viral Pneumonia Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Respiratory Syncytial Virus Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Paediatric Vaccine Market
Vaccines Packaging Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Covid 19 Vaccine Bottle Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
mRNA Vaccines for Infectious Diseases Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pneumococcal 13 valent Conjugate Vaccine Market Research Report 2024
Prostate Cancer Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccine Bottle Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Human Bacterial Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions